Rosana Kapeller raises $77M in bid to make repeatome drugs a reality
Given the choice, Rosana Kapeller would have picked different circumstances to be a first time founder-CEO.
The longtime computational biologist, an early veteran of Millennium and Nimbus, began putting together her latest venture in late 2019, raising the Series A for Rome Therapeutics in the winter and early spring of 2020. And then, of course, the world shut down.
Kapeller, spritely but forthright, acknowledges it’s been a struggle. She went a year without seeing most of the team she was building.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.